Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Igor T Gavrilovic"'
Autor:
Lauren R. Schaff, Mina Lobbous, Dean Carlow, Ryan Schofield, Igor T. Gavrilovic, Alexandra M. Miller, Jacqueline B. Stone, Anna F. Piotrowski, Ugur Sener, Anna Skakodub, Edward P. Acosta, Kevin J. Ryan, Ingo K. Mellinghoff, Lisa M. DeAngelis, Louis B. Nabors, Christian Grommes
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background High-dose methotrexate (HD-MTX) has broad use in the treatment of central nervous system (CNS) malignancies but confers significant toxicity without inpatient hydration and monitoring. Glucarpidase is a bacterial recombinant enzym
Externí odkaz:
https://doaj.org/article/3e9f2e48ef674472afa6c947189513cd
Autor:
Sarin Kitpanit, Anna Lee, Ken L. Pitter, Dan Fan, James C.H. Chow, Brian Neal, Zhiqiang Han, Pamela Fox, Kevin Sine, Dennis Mah, Lara A. Dunn, Eric J. Sherman, Loren Michel, Ian Ganly, Richard J. Wong, Jay O. Boyle, Marc A. Cohen, Bhuvanesh Singh, Cameron W. Brennan, Igor T. Gavrilovic, Vaios Hatzoglou, Bernard O‘Malley, Kaveh Zakeri, Yao Yu, Linda Chen, DaphnaY. Gelblum, Jung Julie Kang, Sean M. McBride, Chiaojung J. Tsai, Nadeem Riaz, Nancy Y. Lee
Publikováno v:
International Journal of Particle Therapy, Vol 6, Iss 4, Pp 1-12 (2020)
Purpose: To demonstrate temporal lobe necrosis (TLN) rate and clinical/dose-volume factors associated with TLN in radiation-naïve patients with head and neck cancer treated with proton therapy where the field of radiation involved the skull base. Ma
Externí odkaz:
https://doaj.org/article/13629738ba634f5f937500601396273a
Autor:
Ingo K. Mellinghoff, Lisa M. DeAngelis, Nikolaus Schultz, Thomas G. Graeber, Katherine S. Panageas, Jason T. Huse, Philip H. Gutin, Anne S. Reiner, Vaios Hatzoglou, Enrico C. Lallana, Scott Peak, Jon Glass, Minhee Won, Ahmet Dogan, Julia Wolfe, Craig H. Moskowitz, Craig S. Sauter, Paul Hamlin, M. Lia Palomba, Ariela Noy, Elina Tsyvkin, Alissa A. Thomas, Elena Pentsova, Antonio Omuro, Craig P. Nolan, Thomas J. Kaley, Igor T. Gavrilovic, Cameron W. Brennan, Viviane S. Tabar, Agnes Viale, Marc Rosenblum, Dan Rohle, Wan-Ying Hsieh, Owen Clark, Donna Nichol, Paolo Codega, Derrek Schartz, Carl Campos, Sarah S. Tang, Nicolaos Palaskas, Alessandro Pastore, Christian Grommes
Supplementary Methods. Supplementary Table S1: Baseline characteristics of PCNSL Patients. Supplementary Table S2: Baseline characteristics of SCNSL patients. Supplementary Table S3: Corticosteroid use. Supplementary Table S4: Genes with Recurrent Mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::846702464e3ab3c289e6186006db05bc
https://doi.org/10.1158/2159-8290.22532099
https://doi.org/10.1158/2159-8290.22532099
Autor:
Barry S. Taylor, Ingo K. Mellinghoff, Lisa M. DeAngelis, Marc Rosenblum, Cameron W. Brennan, Viviane S. Tabar, Timothy A. Chan, Philip H. Gutin, Alexandra M. Miller, Anna F. Piotrowski, Mariza Daras, Adrienne Boire, Christian Grommes, Jacqueline B. Stone, Eli L. Diamond, Thomas J. Kaley, Igor T. Gavrilovic, Antonio Omuro, Elena Pentsova, Craig P. Nolan, T. Jonathan Yang, Kathryn Beal, Allison Hyde, Malbora Manne, Andrew T. McKeown, Shweta S. Chavan, Shahiba Q. Ogilvie, Maryam Pourmaleki, Juliann Chmielecki, Michael E. Goldberg, Diana Mandelker, Zsofia K. Stadler, Angela G. Arnold, David B. Solit, Marc Ladanyi, Ahmet Zehir, Michael F. Berger, Bob T. Li, David M. Hyman, Natalie M. DiStefano, Robert J. Young, Andrew L. Lin, Philip Jonsson
Purpose:The genomic landscape of gliomas has been characterized and now contributes to disease classification, yet the relationship between molecular profile and disease progression and treatment response remain poorly understood.Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::641951579cd359e3e5caf9da91b7120d
https://doi.org/10.1158/1078-0432.c.6528149
https://doi.org/10.1158/1078-0432.c.6528149
Autor:
Barry S. Taylor, Ingo K. Mellinghoff, Lisa M. DeAngelis, Marc Rosenblum, Cameron W. Brennan, Viviane S. Tabar, Timothy A. Chan, Philip H. Gutin, Alexandra M. Miller, Anna F. Piotrowski, Mariza Daras, Adrienne Boire, Christian Grommes, Jacqueline B. Stone, Eli L. Diamond, Thomas J. Kaley, Igor T. Gavrilovic, Antonio Omuro, Elena Pentsova, Craig P. Nolan, T. Jonathan Yang, Kathryn Beal, Allison Hyde, Malbora Manne, Andrew T. McKeown, Shweta S. Chavan, Shahiba Q. Ogilvie, Maryam Pourmaleki, Juliann Chmielecki, Michael E. Goldberg, Diana Mandelker, Zsofia K. Stadler, Angela G. Arnold, David B. Solit, Marc Ladanyi, Ahmet Zehir, Michael F. Berger, Bob T. Li, David M. Hyman, Natalie M. DiStefano, Robert J. Young, Andrew L. Lin, Philip Jonsson
Table S1: Patient-level clinical annotation. Table S2: Sample-level clinical annotation. Table S3: Patient-level treatment lines. Table S4: Gene panels for targeted sequencing. Table S5: Somatic mutations. Table S6: Gene-level copy number alterations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac7a093f2982213652b140852cf8ccb
https://doi.org/10.1158/1078-0432.22472180.v1
https://doi.org/10.1158/1078-0432.22472180.v1
Autor:
Barry S. Taylor, Ingo K. Mellinghoff, Lisa M. DeAngelis, Marc Rosenblum, Cameron W. Brennan, Viviane S. Tabar, Timothy A. Chan, Philip H. Gutin, Alexandra M. Miller, Anna F. Piotrowski, Mariza Daras, Adrienne Boire, Christian Grommes, Jacqueline B. Stone, Eli L. Diamond, Thomas J. Kaley, Igor T. Gavrilovic, Antonio Omuro, Elena Pentsova, Craig P. Nolan, T. Jonathan Yang, Kathryn Beal, Allison Hyde, Malbora Manne, Andrew T. McKeown, Shweta S. Chavan, Shahiba Q. Ogilvie, Maryam Pourmaleki, Juliann Chmielecki, Michael E. Goldberg, Diana Mandelker, Zsofia K. Stadler, Angela G. Arnold, David B. Solit, Marc Ladanyi, Ahmet Zehir, Michael F. Berger, Bob T. Li, David M. Hyman, Natalie M. DiStefano, Robert J. Young, Andrew L. Lin, Philip Jonsson
Figure S1: Distribution of systemic therapies received. Figure S2: Number of sequenced samples per patient. Figure S3: Subgroup-defining genomic lesions in IDH-wildtype and -mutant gliomas. Figure S4: Frequency of mutations in primary tumors. Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4027dff8635107fa41557a7b76e27f
https://doi.org/10.1158/1078-0432.22472186
https://doi.org/10.1158/1078-0432.22472186
Autor:
Jason T. Huse, Lauren E. Abrey, Cameron W. Brennan, Geraldine Faivre, Jianan Zhang, Renata Barradas-Panchal, Juan Sanchez, Elena Pentsova, Viviane Tabar, Raymond E. Baser, Katherine S. Panageas, Anne S. Reiner, Christian Grommes, Ingo Mellinghoff, Andrew B. Lassman, Adilia Hormigo, Craig Nolan, Igor T. Gavrilovic, Timothy A. Chan, Lisa M. DeAngelis, Thomas J. Kaley, Denise D. Correa, Sasan Karimi, Philip Gutin, Kathryn Beal, Antonio Omuro
Purpose: Bevacizumab is associated with decreased vascular permeability that allows for more aggressive radiotherapy schedules. We conducted a phase II trial in newly diagnosed glioblastoma utilizing a novel hypofractionated stereotactic radiotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b87ac63427b1a9f8cffb6435cb25307d
https://doi.org/10.1158/1078-0432.c.6524532
https://doi.org/10.1158/1078-0432.c.6524532
Autor:
Jason T. Huse, Lauren E. Abrey, Cameron W. Brennan, Geraldine Faivre, Jianan Zhang, Renata Barradas-Panchal, Juan Sanchez, Elena Pentsova, Viviane Tabar, Raymond E. Baser, Katherine S. Panageas, Anne S. Reiner, Christian Grommes, Ingo Mellinghoff, Andrew B. Lassman, Adilia Hormigo, Craig Nolan, Igor T. Gavrilovic, Timothy A. Chan, Lisa M. DeAngelis, Thomas J. Kaley, Denise D. Correa, Sasan Karimi, Philip Gutin, Kathryn Beal, Antonio Omuro
Supplementary Data 1 ELIGIBILITY CRITERIA. Supplementary Data 2 HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY PLANNING. Supplementary Data 3 MRI ACQUISITION PARAMETERS AND PROCESSING. Supplementary Data 4 Nanostring-based Tissue Correlates Methods. Supp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a2f416a78d0359c45191f897a37761
https://doi.org/10.1158/1078-0432.22460568
https://doi.org/10.1158/1078-0432.22460568
Autor:
Barry S. Taylor, Ingo K. Mellinghoff, Lisa M. DeAngelis, Marc Rosenblum, Cameron W. Brennan, Viviane S. Tabar, Timothy A. Chan, Philip H. Gutin, Alexandra M. Miller, Anna F. Piotrowski, Mariza Daras, Adrienne Boire, Christian Grommes, Jacqueline B. Stone, Eli L. Diamond, Thomas J. Kaley, Igor T. Gavrilovic, Antonio Omuro, Elena Pentsova, Craig P. Nolan, T. Jonathan Yang, Kathryn Beal, Allison Hyde, Malbora Manne, Andrew T. McKeown, Shweta S. Chavan, Shahiba Q. Ogilvie, Maryam Pourmaleki, Juliann Chmielecki, Michael E. Goldberg, Diana Mandelker, Zsofia K. Stadler, Angela G. Arnold, David B. Solit, Marc Ladanyi, Ahmet Zehir, Michael F. Berger, Bob T. Li, David M. Hyman, Natalie M. DiStefano, Robert J. Young, Andrew L. Lin, Philip Jonsson
List of Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89b012a1aef7c35ac455292434f5b79f
https://doi.org/10.1158/1078-0432.22472183.v1
https://doi.org/10.1158/1078-0432.22472183.v1
Autor:
Hiroaki Goto, Laura Dima, Steven G. DuBois, Ricarda Norenberg, Jordan R. Hansford, Esther De La Cuesta, Juneko E. Grilley-Olson, Ingrid Øra, David S. Hong, Theodore W. Laetsch, Karsten Nysom, Joanna Stefanowicz, Martin Højgaard, Valentina Boni, Hyoung Jin Kang, Julia C. Chisholm, Makoto Tahara, Birgit Geoerger, François Doz, Soledad Gallego-Melcon, David S. Ziegler, Alexander Drilon, Cornelis M. van Tilburg, Hyun Cheol Chung, Anne Thorwarth, Igor T. Gavrilovic, Antoine Italiano, Michael Capra, Sébastien Perreault, Nicolas U. Gerber
Publikováno v:
Neuro-Oncology. 24:997-1007
Background Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1687c873049c47af75e3acbcc822a43d
https://doi.org/10.1093/neuonc/noab274
https://doi.org/10.1093/neuonc/noab274